SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/27/2019
Entire Document
 

8.Settlement and License Agreement dated July 18, 2012, by and between Somaxon, ProCom One, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies

 

9.Settlement and License Agreement dated July 17, 2012, by and between Somaxon, ProCom One, Inc., Mylan Inc. and Mylan Pharmaceuticals Inc.

 

10.Settlement and License Agreement dated February 1, 2013, by and between Somaxon, ProCom One, Inc., Actavis Elizabeth LLC and Actavis Inc.

 

11.Product License and Distribution Agreement dated on September 12, 2017, between Pernix Sleep, Inc. and Pernix Therapeutics LLC

 

Macoven Pharmaceuticals, L.L.C.

 

1.Midrin License, Distribution and Supply Agreement dated March 25, 2013 by and between Macoven Pharmaceuticals, L.L.C. and ECI Pharmaceuticals, LLC.

 

2.First Amendment to the Midrin License, Distribution and Supply Agreement, dated December 23, 2014, by and between Macoven Pharmaceuticals, L.L.C. and ECI Pharmaceuticals, LLC.

 

Respicopea Inc.

 

1.Amended and Restated Patent License Agreement dated May 14, 2012 between Respicopea Limited and Respicopea Inc.

 

Pernix Ireland Limited

 

1.License Agreement dated November 27, 2007 by and between Zogenix, Inc and Daravita Limited, assigned to Pernix Ireland Limited under an Asset Purchase Agreement dated March 10, 2015 by and between Pernix Ireland Limited and Zogenix, Inc. wherein Pernix acquired a license to the marks herein. Pernix Ireland Limited, a subsidiary of Pernix Therapeutics Holdings, Inc., assigned rights acquired from Zogenix to Pernix Ireland Pain Limited, a separate subsidiary of Pernix Therapeutics Holdings, Inc. As of August 21, 2017, Pernix Ireland Pain Limited is now Pernix Ireland Pain Designated Activity Company

 

2.Product Development and Commercialization Agreement dated June 2003 by and between Pozen, Inc. and Glaxo Group Ltd. (amended as of May 2014 and July 2014) was assigned by GSK to Pernix Ireland Limited (May 14, 2014).

 

a.Settlement Agreement dated July 8, 2013 by and among Pozen Inc, Sun Pharma Global FZE and Sun Pharmaceutical Industries Ltd.

 

b.Settlement Agreement dated April 13, 2010 by and between Pozen Inc. and Teva Pharmaceuticals USA, Inc.

 

3.License Agreement dated November 27, 2007 by and between Elan Pharma International Ltd. and Zogenix, Inc, as assigned to Pernix Ireland Limited under the Asset Purchase Agreement dated March 10, 2015 by and between Pernix Ireland Limited and Zogenix, Inc. Pernix Ireland Limited, a subsidiary of Pernix Therapeutics Holdings, Inc., assigned rights acquired from Zogenix to Pernix Ireland Pain Limited, a separate subsidiary of Pernix Therapeutics Holdings, Inc.

 

a.First Amendment to License Agreement dated as of September 28, 2009 by and between Elan Pharma International Ltd. and Zogenix, Inc.

 

b.Second Amendment to License Agreement dated as of March 12, 2013 by and between Alkermes Pharma Ireland Limited and Zogenix, Inc.

 

c.Third Amendment to License Agreement Dated as of September 5, 2014 by and between Alkermes Science One Limited and Zogenix, Inc.

 

d.Fourth Amendment to License Agreement dated as of March 5, 2015 by and between Daravita Limited and Zogenix, Inc.

 

Schedule 4.5

Page - 15